Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034)
The dynamics of the cutaneous T-cell lymphoma market are anticipated to change owing to the improvement in research and development activities, increasing prevalence, and the rising geriatric population. Additionally, the expected launch of therapies such as HyBryte, PTX-100, Lacutamab, BMS-986369, ONO-4685, and others will also boost the CTCL market growth.
DelveInsight's Cutaneous T-cell Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging cutaneous T-cell lymphoma drugs, market share of individual therapies, and current and forecasted cutaneous T-cell lymphoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Cutaneous T-cell Lymphoma Market Report According to DelveInsight's analysis, the market size for cutaneous T-cell lymphoma was found to be USD 995 million in the 7MM in 2024.
in the 7MM in 2024. The United States accounted for the highest cutaneous T-cell lymphoma market size, approximately 70% of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Among the 7MM, the US accounted for the highest number of cases of CTCL in 2024, with nearly 3,000 cases. These cases are anticipated to increase by 2034.
cases. These cases are anticipated to increase by 2034. Prominent cutaneous T-cell lymphoma companies, including Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, and others, are actively working on innovative cutaneous T-cell lymphoma drugs.
and others, are actively working on innovative cutaneous T-cell lymphoma drugs. Some of the key cutaneous T-cell lymphoma therapies in the pipeline include HyBryte (Synthetic Hypericin/SGX301), PTX-100, Lacutamab (IPH4102), BMS-986369 (Golcadomide), ONO-4685 , and others. These novel cutaneous T-cell lymphoma therapies are anticipated to enter the cutaneous T-cell lymphoma market in the forecast period and are expected to change the market.
, and others. These novel cutaneous T-cell lymphoma therapies are anticipated to enter the cutaneous T-cell lymphoma market in the forecast period and are expected to change the market. By 2034, among all the therapies in the late stage, the highest revenue is expected to be generated by POTELIGEO in the 7MM.
in the 7MM. In May 2025, 4SC received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for KINSELBY, intended for the treatment of advanced-stage CTCL, leading to the decision to discontinue its further development and commercialization.
received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for KINSELBY, intended for the treatment of advanced-stage CTCL, leading to the decision to discontinue its further development and commercialization. In March 2025, Prescient Therapeutics opened the first clinical site for its Phase IIa study of PTX-100 in patients with relapsed or refractory CTCL.
opened the first clinical site for its Phase IIa study of PTX-100 in patients with relapsed or refractory CTCL. In February 2025, Citius Pharmaceuticals and its oncology-focused subsidiary, Citius Oncology, announced that LYMPHIR has been assigned a unique, permanent HCPCS J-code (J9161) by the CMS. The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement.
Discover which cutaneous T-cell lymphoma medications are expected to grab the market share @ Cutaneous T-cell Lymphoma Market Report
Cutaneous T-cell Lymphoma Overview
Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that begins in the skin, arising from T lymphocytes—a type of white blood cell that plays a key role in immune defense against infections and cancer. Unlike other lymphomas that typically originate in the lymph nodes or internal organs, CTCL starts in the skin, which itself functions as a major lymphoid organ. Although B-cell lymphomas are generally more common, T-cell lymphomas like CTCL are more frequently found in the skin.
Diagnosing CTCL involves a comprehensive clinical evaluation, including a review of symptoms, physical examination, detailed medical history, and specialized diagnostic tests. These tests help identify the exact type and stage of the disease and guide treatment planning. Skin biopsies are a standard diagnostic tool, particularly because early CTCL can mimic benign skin disorders such as psoriasis. In many cases, multiple biopsies are needed to establish a definitive diagnosis due to the subtle and variable nature of early-stage CTCL.
Cutaneous T-cell Lymphoma Epidemiology Segmentation
The cutaneous T-cell lymphoma epidemiology section provides insights into the historical and current cutaneous T-cell lymphoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The cutaneous T-cell lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of CTCL
Type-specific Cases of CTCL
Gender-specific Cases of CTCL
Stage-specific Cases of CTCL
Treatment-eligible Pool in Early and Advanced Stages of CTCL
Download the report to understand which factors are driving cutaneous T-cell lymphoma epidemiology trends @ Cutaneous T-cell Lymphoma Treatment Algorithm
Cutaneous T-cell Lymphoma Treatment Market
The treatment strategy for mycosis fungoides and Sézary syndrome, both forms of cutaneous T-cell lymphoma, varies depending on the extent of skin involvement and whether the disease has spread. Mycosis fungoides typically responds well to therapies directed at the skin or the whole body, whereas Sézary syndrome usually necessitates systemic treatment approaches.
VALCHLOR (mechlorethamine) is the first and only FDA-approved topical formulation of mechlorethamine for patients with Stage IA or IB mycosis fungoides-type CTCL who have previously undergone skin-directed therapy. For patients with early-stage disease, topical corticosteroids are considered the first-line treatment. Additionally, topical Toll-like Receptor (TLR) agonists, which stimulate local production of interferons and cytokines to promote tumor cell death and enhance the immune response, have shown clinical benefit in managing limited-stage mycosis fungoides.
In cases of advanced-stage mycosis fungoides or Sézary syndrome, a comprehensive and multidisciplinary approach is required. Management often involves combinations of skin-directed therapies, immune-modulating agents, and sequential systemic chemotherapy. However, for early-stage disease, multi-agent chemotherapy is generally avoided. Instead, a risk- and stage-adapted strategy, aligned with the National Comprehensive Cancer Network (NCCN) Guidelines, is typically used. This includes the use of biologic-response modifiers (such as bexarotene and interferon-alpha), histone deacetylase (HDAC) inhibitors (like romidepsin), or targeted therapies such as monoclonal antibodies or antibody-drug conjugates (e.g., mogamulizumab, brentuximab vedotin). Treatment choices are tailored to each patient, taking into account factors such as age, overall health, disease stage and burden, progression rate, and prior treatments.
For advanced-stage CTCL (Stages IIB–IV), effective systemic therapies include HDAC inhibitors such as ISTODAX (romidepsin) and ZOLINZA (vorinostat). Notably, vorinostat was the first HDAC inhibitor to gain FDA approval in 2006 for treating progressive, persistent, or relapsing CTCL.
Learn more about the cutaneous T-cell lymphoma treatment options @ Cutaneous T-cell Lymphoma Treatment Guidelines
Cutaneous T-cell Lymphoma Emerging Drugs and Companies
Some of the drugs in the pipeline include HyBryte (Soligenix and Sterling Pharma Solutions), PTX-100 (Prescient Therapeutics), Lacutamab (Innate Pharma), Golcadomide (Bristol Myers Squibb), and others.
HyBryte is a topical formulation containing hypericin, one of the most light-sensitive compounds known. The product has been granted both Orphan Drug Designation and Fast Track Designation by the U.S. FDA, along with orphan status from the European Medicines Agency (EMA). Soligenix showcased new clinical data supporting HyBryte's use in treating cutaneous T-cell lymphoma at two major events: the United States Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6, 2025, and the American Academy of Dermatology (AAD) Annual Meeting held from March 7 to 11, 2025.
In an April 2024 press release, the company stated it expects to report top-line results from its 18-week confirmatory FLASH2 study, being conducted in both the U.S. and Europe, during the second half of 2026.
PTX-100 is a novel, first-in-class agent that inhibits a key enzyme involved in cancer progression by targeting the oncogenic Ras signaling pathway. The drug is currently undergoing a Phase IIa trial in patients with relapsed or refractory CTCL, with potential progression to a Phase IIb registration study. As outlined in Prescient Therapeutics' May 2025 investor update, the company expects to receive Orphan Drug Designation in Europe by Q3 2025. Additionally, an interim review of Phase IIa trial data is planned for Q4 2025 or early 2026. Prescient also announced in May 2025 that the first patient had been successfully dosed in this ongoing Phase IIa study.
Lacutamab is a humanized, first-in-class antibody targeting KIR3DL2, designed to induce cytotoxicity. It is being tested in an open-label, multicohort Phase II study in CTCL and another Phase II study in peripheral T-cell lymphoma (PTCL). According to Innate Pharma's most recent annual update from May 2025, the company aims to begin a Phase III trial of lacutamab, with plans to pursue accelerated approval by 2027.
Furthermore, long-term follow-up data from the TELLOMAK Phase II trial, focusing on patients with Sézary syndrome and mycosis fungoides, will be presented at the 2025 ASCO Annual Meeting on June 2 in Chicago, Illinois.
The anticipated launch of these emerging cutaneous T-cell lymphoma therapies are poised to transform the cutaneous T-cell lymphoma market landscape in the coming years. As these cutting-edge cutaneous T-cell lymphoma therapies continue to mature and gain regulatory approval, they are expected to reshape the cutaneous T-cell lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for cutaneous T-cell lymphoma, visit @ Cutaneous T-cell Lymphoma Management
Cutaneous T-cell Lymphoma Market Dynamics
The cutaneous T-cell lymphoma market dynamics are anticipated to change in the coming years. The prognosis for most patients with CTCL is promising, especially with early detection and timely treatment, which can enable decades of survival with ongoing care. However, the disease's heterogeneity and involvement of multiple pathways create a strong foundation for the development of diverse targeted therapies. Emerging evidence supporting PTX-100's superior efficacy and safety over LYMPHIR further underscores the potential of targeting GGT1 inhibition. Combined with the limited pipeline activity in CTCL, this presents a significant opportunity for drug developers to innovate and bring novel therapies to an underserved market.
Furthermore, many potential therapies are being investigated for the treatment of cutaneous T-cell lymphoma, and it is safe to predict that the treatment space will significantly impact the cutaneous T-cell lymphoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the cutaneous T-cell lymphoma market in the 7MM.
However, several factors may impede the growth of the cutaneous T-cell lymphoma market. The diagnosis and treatment of cutaneous T-cell lymphoma remain challenging due to several factors: multiple biopsies are often required for a definitive diagnosis, potentially delaying appropriate treatment; the underlying mechanisms driving CTCL-associated pruritus are still poorly understood despite advances in research; targeted therapies frequently face issues of limited tolerance and efficacy, leading to discontinuation from toxicity or resistance; and the recent negative opinion and discontinuation of KINSELBY underscore regulatory risks, casting uncertainty over the future development of similar therapies.
Moreover, cutaneous T-cell lymphoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cutaneous T-cell lymphoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cutaneous T-cell lymphoma market growth. Cutaneous T-cell Lymphoma Report Metrics Details Study Period 2020–2034 Cutaneous T-cell Lymphoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Cutaneous T-cell Lymphoma Market CAGR 7.1% Cutaneous T-cell Lymphoma Market Size in 2024 USD 995 Million Key Cutaneous T-cell Lymphoma Companies Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, Kyowa Hakko Kirin, Pfizer (Seagen), Takeda, Helsinn Therapeutics, Citius Pharmaceuticals, Valeant Pharmaceuticals, Bausch Health, and others Key Cutaneous T-cell Lymphoma Therapies HyBryte (Synthetic Hypericin/SGX301), PTX-100, Lacutamab (IPH4102), BMS-986369 (Golcadomide), ONO-4685, POTELIGEO, ADCETRIS, VALCHLOR/LEDAGA, LYMPHIR, TARGRETIN, ISTODAX, and others
Scope of the Cutaneous T-cell Lymphoma Market Report Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and emerging therapies
Cutaneous T-cell Lymphoma current marketed and emerging therapies Cutaneous T-cell Lymphoma Market Dynamics: Conjoint Analysis of Emerging Cutaneous T-cell Lymphoma Drugs
Conjoint Analysis of Emerging Cutaneous T-cell Lymphoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cutaneous T-cell Lymphoma Market Access and Reimbursement
Discover more about cutaneous T-cell lymphoma drugs in development @ Cutaneous T-cell Lymphoma Clinical Trials
Table of Contents 1 Key Insights 2 CTCL Market Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 CTCL Market Overview at a Glance 7 Disease Background and Overview 8 CTCL Treatment 8.1 Treatment of Limited-stage Mycosis Fungoides/Sézary Syndrome 8.2 Treatment of Advanced-stage Mycosis Fungoides/Sezary Syndrome 8.3 CTCL Treatment Guidelines 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale 9.3 Total Incident Cases of CTCL in the 7MM 9.4 The United States 9.5 EU4 and the UK 9.6 Japan 10 Patient Journey 11 CTCL Marketed Drugs 11.1 Key Competitors 11.2 POTELIGEO (mogamulizumab): Kyowa Hakko Kirin 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Developmental Activities 11.2.4 Clinical Development 11.2.4.1 Clinical Trial Information 11.2.5 Safety and Efficacy 11.2.6 Analyst Views 11.3 ADCETRIS (brentuximab vedotin): Pfizer (Seagen) and Takeda 11.4 VALCHLOR/LEDAGA (mechlorethamine): Helsinn Therapeutics 11.5 LYMPHIR/REMITORO/E7777/ONTAK (denileukin diftitox): Citius Pharmaceuticals 12 Discontinued Therapy 12.1 KINSELBY (resminostat): 4SC 12.1.1 Product Description 12.1.2 Other Developmental Activities 12.1.3 Clinical Development 12.1.3.1 Clinical Trials Information 12.1.4 Safety and Efficacy 12.1.5 Analyst Views 13 CTCL Emerging Therapies 13.1 Key Cross Competition 13.2 HyBryte (Synthetic Hypericin/SGX301): Soligenix and Sterling Pharma Solutions 13.2.1 Product Description 13.2.2 Other Developmental Activities 13.2.3 Clinical Development 13.2.3.1 Clinical Trials Information 13.2.4 Safety and Efficacy 13.2.5 Analyst Views 13.3 PTX-100: Prescient Therapeutics 13.4 Lacutamab (IPH4102): Innate Pharma 14 CTCL: Seven Major Market Analysis 14.1 Key Findings 14.2 Market Outlook 14.3 Conjoint Analysis 14.4 Key Market Forecast Assumptions 14.4.1 Cost Assumptions and Rebate 14.4.2 Pricing Trends 14.4.3 Analogue Assessment 14.4.4 Launch Year and Therapy Uptake 14.5 Total Market Size of CTCL in the 7MM 14.6 The United States Market Size 14.7 EU4 and the UK Market Size 14.8 Japan 15 Unmet Needs 16 SWOT Analysis 17 KOL Views 18 CTCL Market Access and Reimbursement 18.1 United States 18.2 EU4 and the UK 18.3 Japan 18.4 Market Access and Reimbursement of CTCL 19 Bibliography 20 Report Methodology
Related Reports
Cutaneous T-cell Lymphoma Pipeline
Cutaneous T-cell Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CTCL companies, including Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc., among others.
Non-Hodgkin's Lymphoma Market
Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others.
Non-Hodgkin's Lymphoma Pipeline
Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others.
Peripheral T-Cell Lymphoma Market
Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others.
Diffuse Large B-cell Lymphoma Market
Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Former CIA Insider Highlights America's Buried Advantage in Online Presentation
By GlobeNewswire Published on July 28, 2025, 02:00 IST Washington, D.C., July 27, 2025 (GLOBE NEWSWIRE) — Rediscovering America's Strategic Core In a released presentation , renowned former national security advisor Jim Rickards warns that the next major shift in U.S. policy may come not from Wall Street or Washington—but from beneath the surface of federally controlled lands. 'This story is not about real estate… the government retained the most valuable part'. Rickards points to a dormant but active legal provision—originally designed to encourage domestic growth—which may now hold the key to America's technological future. The Invisible Wiring of Modern Power The materials Rickards identifies are not commodities in the traditional sense—they are foundational enablers of global advancement: Application Mineral Inputs AI Chips & Data Centers Silicon, gallium, germanium, copper EV Batteries Lithium, cobalt, nickel, manganese, graphite Missile Systems & Drones Neodymium, dysprosium, samarium, rare earth alloys Satellite Navigation Indium, tantalum, beryllium, aluminum 'These seemingly obscure minerals… they're the building blocks of everything from NVIDIA chips to advanced military weapons'. Sources: U.S. Department of Energy CSIS Visual Capitalist A 150-Year-Old Law, Still in Effect Rickards centers the opportunity on Title 30—a little-known federal statute from the 1800s that allowed Americans to claim rights to public lands, which were often rich in mineral deposits. 'Back then, anyone could make a claim… pay $2 to $5 per acre… and do a minimal amount of work'. The framework still exists—and Rickards believes it may quietly be resurfacing to address modern strategic needs without requiring congressional debate. Technology May Be the Catalyst Rickards believes a convergence of technology and geopolitics is making this moment different: The use of AI mapping tools to identify previously unreachable mineral deposits The Pentagon's direct involvement in securing U.S. rare-earth supply chains Escalating foreign control over strategic mineral exports 'We have truly massive mineral wealth here. It's not hard to extract. We know where it is. And how to get it' About Jim Rickards Jim Rickards is a former advisor to the CIA, Pentagon, White House, and Treasury. His work has guided U.S. leadership during global crises including the Iran Hostage Situation and the 2008 financial collapse. He is the editor of Strategic Intelligence , a monthly report on national security, macroeconomics, and resource policy. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
Perseus Mining June Quarter Report
By GlobeNewswire Published on July 28, 2025, 03:40 IST Perth, July 28, 2025 (GLOBE NEWSWIRE) — JUNE 2025 QUARTER REPORT Continued strong performance of Perseus Mining's operations grows cash & bullion balance to US$827 million PERTH, Western Australia/July 28, 2025/Perseus Mining Limited ('Perseus' or the 'Company') (TSX & ASX: PRU) reports on its activities for the three months' period ended June 30, 2024 (the 'Quarter'). Below is a summary of the release. The full report is available at and Key operating indicators and highlights for the June 2025 quarter (Q4 FY25) include: PERFORMANCE INDICATOR UNIT MARCH 2025 QUARTER JUNE 2025 QUARTER JUNE 2025 HALF YEAR 2025 FINANCIAL YEAR Gold recovered Ounces 121,605 121,237 242,843 496,551 Gold poured Ounces 122,915 119,868 242,782 495,984 Production Cost US$/ounce 977 1,038 1,008 980 All-In Site Cost (AISC) US$/ounce 1,209 1,417 1,313 1,235 Gold sales Ounces 117,585 131,242 248,826 494,343 Average sales price US$/ounce 2,462 2,977 2,734 2,543 Notional Cashflow US$ million 152 189 345 650 Record 12-month rolling average Total Recordable Injury Frequency Rate (TRIFR) of 0.60 is well below industry average. is well below industry average. Quarterly gold production of 121,237 ounces at a weighted average AISC of US$1,417 per ounce enabled Perseus to achieve production guidance and better cost guidance for June 2025 half year (2H FY25) and 2025 financial year (FY25) . at a weighted average enabled Perseus to for June 2025 half year (2H FY25) and 2025 financial year (FY25) Average gold sales of 131,242 ounces with a weighted average gold sales price of US$2,977 per ounce. with a weighted average Average cash margin of US$1,560 per ounce of gold produced, giving notional operating cashflow of US$189 million. of gold produced, giving Perseus's gold production and AISC outlook for the next 5 years includes average gold production of 515,000 – 535,000 ounces per year, at an average AISC of US$1,400 – US$1,500 per ounce . includes at an average . For the 2026 financial year ( FY26 ), gold production guidance is 400,000 – 440,000 ounces while AISC guidance is US$1,460 – 1,620 per ounce , representing a temporary dip in the longer-term outlook for the Company. ), is while is , representing a temporary dip in the longer-term outlook for the Company. A Final Investment Decision (FID) was taken during the quarter to develop the Nyanzaga Gold Project (NGP). Site works are accelerating and are on-budget and on schedule, consistent with the target of first gold production in January 2027. was taken during the quarter to develop the Site works are accelerating and are on-budget and on schedule, consistent with the target of first gold production in January 2027. Outstanding infill drilling results at NGP have Perseus on target for a Mineral Resource and Ore Reserve upgrade in Q3 FY26 resulting in a possible mine life extension. have Perseus on target for a Mineral Resource and Ore Reserve upgrade in Q3 FY26 resulting in a possible mine life extension. Available cash and bullion of US$827 million, plus liquid listed securities of US$118 million , notwithstanding significant payments associated with development of NGP, corporate tax, dividends and share buy-back payments. plus liquid , notwithstanding significant payments associated with development of NGP, corporate tax, dividends and share buy-back payments. Zero debt and available undrawn debt capacity of US$300 million at quarter-end. and available at quarter-end. Perseus's A$100 million buy-back of its shares continued between blackout periods during the quarter and is currently ~73% complete with 22,995,853 shares purchased and subsequently cancelled. GROUP GOLD PRODUCTION AND COST GUIDANCE Group gold production and AISC market guidance for FY26 is as follows: Table 10: Production and AISC Guidance PARAMETER UNITS 2026 FINANCIAL YEAR FORECAST Yaouré Gold Mine Production Ounces 168,000 – 184,000 All-in Site Cost USD per ounce $1,500 – $1,660 Edikan Gold Mine Production Ounces 154,000 – 169,000 All-in Site Cost USD per ounce $1,420 – $1,570 Sissingué Gold Mine Production Ounces 78,000 – 87,000 All-in Site Cost USD per ounce $1,470 – $1,620 PERSEUS GROUP Production Ounces 400,000 – 440,000 All-in Site Cost USD per ounce $1,460 – $1,620 The rise relative to prior periods in Perseus's guided AISC in FY25 as noted above can be attributed to a range of factors which have been considered in forecasting future operating costs, including an assumed gold price of US$2,700 per ounce for the period. A trend of rising costs is evident in the global gold sector, including in West Africa, driven by a range of factors, not the least of which is a steady increase in royalties and indirect charges payable to host governments (and others) which are a function of prevailing gold prices. In other words, as the price of gold rises, so too do expectations by host governments and host communities of an increasing share of the higher gold prices. This occurs in the form of higher royalty and gold price linked indirect charges by governments as well as an increase in the cost of land access and contributions to community assistance funds, demanded by host communities. Other factors that impact Perseus's operating costs include the rising cost of wages, freight costs and therefore consumables and the fact that in some operations, as they mature, haul distances and elevations increase and facilities such as tailings dams require expansion. In addition, forecast costs are impacted by site specific factors outside of Perseus's control such as at Yaouré, where an expected interruption is expected to the availability of power from the Ivorian power grid in H1 FY26 caused by planned maintenance of power stations that contribute power to the grid. It has been assumed that Perseus will be required to make significantly more use of its standby generators during this period which operate at a cost that is materially above grid power costs. SEptember 2025 QUARTER EVENTS & ANNOUNCEMENTS 22 July – Resource Definition Drilling Update for Nyanzaga Gold Project 28 July – June 2025 Quarterly Report & Webinar 27 August – Annual Mineral Resources and Ore Reserves Update 28 August – Financial Year 2024 Annual Report & Webinar 14-17 September – Mining Forum Americas Competent Person Statement All production targets referred to in this release are underpinned by estimated Ore Reserves which have been prepared by competent persons in accordance with the requirements of the JORC Code. Edikan The information in this release that relates to the Open Pit and Underground Mineral Resources and Ore Reserve at Edikan was updated by the Company in a market announcement 'Perseus Mining updates Mineral Resources and Ore Reserves' released on 21August 2024. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Edikan Gold Mine, Ghana' dated 7 April 2022 continue to apply. Sissingué, Fimbiasso and Bagoé The information in this release that relates to the Mineral Resources and Ore Reserve at the Sissingué complex was updated by the Company in a market announcement 'Perseus Mining updates Mineral Resources and Ore Reserves' released on 21 August 2024. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Sissingué Gold Project, Côte d'Ivoire' dated 29 May 2015 continue to apply. Yaouré The information in this release that relates to the Open Pit and Underground Mineral Resources and Ore Reserve at Yaouré was updated by the Company in a market announcement 'Perseus Mining updates Mineral Resources and Ore Reserves' released on 21 August 2024. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Yaouré Gold Project, Côte d'Ivoire' dated 19 December 2023 continue to apply. Nyanzaga Gold Project The information in this report that relates to the Mineral Resources and Ore Reserve at Nyanzaga was updated by the Company in a market announcement 'Perseus Mining proceeds with development of the Nyanzaga Gold Project' released on 28 April 2025. The Company confirms that all material assumptions underpinning those estimates and the production targets, or the forecast financial information derived therefrom, in that market release continue to apply and have not materially changed. The Company further confirms that material assumptions underpinning the estimates of Ore Reserves described in 'Technical Report — Nyanzaga Gold Project' dated 10 June 2025 continue to apply. The information in this report relating to Nyanzaga exploration results was first reported by the Company in compliance with the JORC Code 2012 and NI43-101 in a market update 'Perseus Mining Delivers Encouraging Drilling Results from its Current Drill Program at the Nyanzaga Gold Project' released on 22 July 2025. The Company confirms that it is not aware of any new information or data that materially affect the information in that market release. Meyas Sand Gold Project The information in this report that relates to the mineral resources and probable reserves of the Meyas Sand Gold Project was first reported by the Company in a market announcement 'Perseus Enters Into Agreement to Acquire Orca Gold Inc.' released on 28 February 2022. The Company confirms it is not in possession of any new information or data relating to those estimates that materially impacts of the reliability of the estimate of the Company's ability to verify the estimate as a mineral resource or ore reserve in accordance with Appendix 5A (JORC Code) and the information in that original market release continues to apply and have not materially changed. These estimates are prepared in accordance with Canadian National Instrument 43-101 standards and have not been reported in accordance with the JORC Code. A competent person has not done sufficient work to classify the resource in accordance with the JORC Code and it is uncertain that following evaluation and/or further exploration work that the estimate will be able to be reported as a mineral resource or ore reserve in accordance with the JORC Code. This release and all technical information regarding Orca's NI 43-101 have been reviewed and approved by Adrian Ralph, a Qualified Person for the purposes of NI 43-101. Caution Regarding Forward Looking Information: This report contains forward-looking information which is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management of the Company believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Assumptions have been made by the Company regarding, among other things: the price of gold, continuing commercial production at the Yaouré Gold Mine, the Edikan Gold Mine and the Sissingué Gold Mine without any major disruption, development of a mine at Nyanzaga, the receipt of required governmental approvals, the accuracy of capital and operating cost estimates, the ability of the Company to operate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used by the Company. Although management believes that the assumptions made by the Company and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any anticipated future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the actual market price of gold, the actual results of current exploration, the actual results of future exploration, changes in project parameters as plans continue to be evaluated, as well as those factors disclosed in the Company's publicly filed documents. Readers should not place undue reliance on forward-looking information. Perseus does not undertake to update any forward-looking information, except in accordance with applicable securities laws. This market announcement was authorised for release by the Board of Perseus Mining Limited. ASX/TSX CODE: PRU CAPITAL STRUCTURE: Ordinary shares: 1,353,991,309 Performance rights: 9,328,134 REGISTERED OFFICE: Level 2 437 Roberts Road Subiaco WA 6008 Telephone: +61 8 6144 1700 DIRECTORS: Rick Menell Non-Executive Chairman Jeff Quartermaine Managing Director & CEO Amber Banfield Non-Executive Director Elissa Cornelius Non-Executive Director Dan Lougher Non-Executive Director John McGloin Non-Executive Director James Rutherford Non-Executive Director CONTACTS: Jeff Quartermaine Managing Director & CEO [email protected] Stephen Forman Investor Relations +61 484 036 681 [email protected] Nathan Ryan Media +61 420 582 887 [email protected] Attachment TSX Release_Q4 FY25 Quarterly Report_Final Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
9 hours ago
- Business Upturn
TOP RANKED ROSEN LAW FIRM Encourages Vera Bradley, Inc. Investors to Inquire About Securities Class Action Investigation
NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera Bradley may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Vera Bradley securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On June 11, 2025, Vera Bradley announced its financial results for the first quarter of the 2026 fiscal year. Commenting on the results, Vera Bradley's CEO stated that '[o]ur first quarter results were disappointing as top line and profitability trends from the previous several quarters continued.' On this news, Vera Bradley's stock fell 19% on June 11, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
